Published in J Immunol on January 01, 2005
Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med (2006) 8.41
Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases. Nat Rev Immunol (2010) 3.69
IL-17-producing human peripheral regulatory T cells retain suppressive function. Blood (2009) 3.04
The immune paradox of sarcoidosis and regulatory T cells. J Exp Med (2006) 2.35
Skin-resident T cells: the ups and downs of on site immunity. J Invest Dermatol (2009) 2.31
Immunology of psoriasis. Annu Rev Immunol (2014) 2.06
Regulatory T-cell compartmentalization and trafficking. Blood (2006) 1.86
IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells. J Immunol (2009) 1.77
Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells. J Exp Med (2008) 1.67
B cell depletion enhances T regulatory cell activity essential in the suppression of arthritis. J Immunol (2011) 1.59
Lymphocytes, neuropeptides, and genes involved in alopecia areata. J Clin Invest (2007) 1.56
Human regulatory T cells and autoimmunity. Eur J Immunol (2008) 1.54
Levels and function of regulatory T cells in patients with polymorphic light eruption: relation to photohardening. Br J Dermatol (2015) 1.43
Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis. Arch Neurol (2009) 1.42
Impaired in vitro regulatory T cell function associated with Wiskott-Aldrich syndrome. Clin Immunol (2007) 1.40
Psoriasis genetics: breaking the barrier. Trends Genet (2010) 1.38
Stat3 phosphorylation mediates resistance of primary human T cells to regulatory T cell suppression. J Immunol (2011) 1.26
Dendritic cells as controllers of antigen-specific Foxp3+ regulatory T cells. J Dermatol Sci (2009) 1.23
Foxp3+ T-regulatory cells in Sjogren's syndrome: correlation with the grade of the autoimmune lesion and certain adverse prognostic factors. Am J Pathol (2008) 1.23
New insights of T cells in the pathogenesis of psoriasis. Cell Mol Immunol (2012) 1.21
Aging and human CD4(+) regulatory T cells. Mech Ageing Dev (2009) 1.20
Multiple sclerosis and regulatory T cells. J Clin Immunol (2008) 1.17
Pertussis toxin as an adjuvant suppresses the number and function of CD4+CD25+ T regulatory cells. Eur J Immunol (2006) 1.16
Regulatory T cells and human disease. Clin Dev Immunol (2007) 1.12
Regulatory T cells in human disease and their potential for therapeutic manipulation. Immunology (2006) 1.12
A rapid diagnostic test for human regulatory T-cell function to enable regulatory T-cell therapy. Blood (2012) 1.10
Reduced skin homing by functional Treg in vitiligo. Pigment Cell Melanoma Res (2010) 1.09
Translational mini-review series on Th17 cells: development of mouse and human T helper 17 cells. Clin Exp Immunol (2009) 1.05
Human regulatory T cells: a unique, stable thymic subset or a reversible peripheral state of differentiation? Immunol Lett (2007) 1.05
Progress in understanding the immunopathogenesis of psoriasis. Actas Dermosifiliogr (2009) 1.04
T cell receptor CDR3 sequence but not recognition characteristics distinguish autoreactive effector and Foxp3(+) regulatory T cells. Immunity (2009) 0.99
Regulation generation: the suppressive functions of human regulatory T cells. Crit Rev Immunol (2012) 0.98
The pro-inflammatory role of TGFβ1: a paradox? Int J Biol Sci (2012) 0.97
Immunological and histological evaluation of clinical samples from psoriasis patients treated with anti-CD6 itolizumab. MAbs (2014) 0.97
CD2 costimulation reveals defective activity by human CD4+CD25(hi) regulatory cells in patients with multiple sclerosis. J Immunol (2011) 0.96
IL-17 in psoriasis: implications for therapy and cardiovascular co-morbidities. Cytokine (2013) 0.95
Signal peptide cleavage is essential for surface expression of a regulatory T cell surface protein, leucine rich repeat containing 32 (LRRC32). BMC Biochem (2011) 0.95
Changes in circulating lymphocyte subpopulations following administration of the leucocyte function-associated antigen-3 (LFA-3)/IgG1 fusion protein alefacept. Clin Exp Immunol (2007) 0.92
TGF-beta-dependent suppressive function of Tregs requires wild-type levels of CD18 in a mouse model of psoriasis. J Clin Invest (2008) 0.91
Regulatory T-cell trafficking: from thymic development to tumor-induced immune suppression. Crit Rev Immunol (2010) 0.90
Psoriasis patients exhibit impairment of the high potency CCR5(+) T regulatory cell subset. Clin Immunol (2013) 0.89
Naturally-occurring regulatory T cells are increased in inflamed portal tracts with cholangiopathy in primary biliary cirrhosis. J Clin Pathol (2006) 0.89
Vitamin D and the skin: Focus on a complex relationship: A review. J Adv Res (2014) 0.88
Decreased 4-1BB expression on CD4+CD25 high regulatory T cells in peripheral blood of patients with multiple sclerosis. Clin Exp Immunol (2008) 0.87
Reactive oxygen species prevent imiquimod-induced psoriatic dermatitis through enhancing regulatory T cell function. PLoS One (2014) 0.86
Origin and functions of pro-inflammatory cytokine producing Foxp3+ regulatory T cells. Cytokine (2015) 0.85
Etanercept downregulates the Th17 pathway and decreases the IL-17+/IL-10+ cell ratio in patients with psoriasis vulgaris. J Clin Immunol (2012) 0.85
Molecular Phenotyping Small (Asian) versus Large (Western) Plaque Psoriasis Shows Common Activation of IL-17 Pathway Genes but Different Regulatory Gene Sets. J Invest Dermatol (2016) 0.85
Photodynamic therapy with the silicon phthalocyanine pc 4 induces apoptosis in mycosis fungoides and sezary syndrome. Adv Hematol (2010) 0.82
Autoimmune Liver Disease Post-Liver Transplantation: A Summary and Proposed Areas for Future Research. Transplantation (2016) 0.81
Heme oxygenase-1 induction attenuates imiquimod-induced psoriasiform inflammation by negative regulation of Stat3 signaling. Sci Rep (2016) 0.81
Plasmin plays an essential role in amplification of psoriasiform skin inflammation in mice. PLoS One (2011) 0.80
Photo(chemo)therapy reduces circulating Th17 cells and restores circulating regulatory T cells in psoriasis. PLoS One (2013) 0.80
Role of immune-regulatory cells in skin pathology. J Leukoc Biol (2010) 0.80
Lifting the silver flakes: the pathogenesis and management of chronic plaque psoriasis. Biomed Res Int (2013) 0.80
The dark side of regulatory T cells in psoriasis. J Invest Dermatol (2011) 0.80
Predominance of activated, clonally expanded T helper type 17 cells within the CD4+ T cell population in psoriatic lesions. Clin Exp Immunol (2013) 0.79
Immunologic biomarkers for clinical and therapeutic management of psoriasis. Mediators Inflamm (2014) 0.79
Role of CD4CD25FOXP3 Regulatory T Cells in Psoriasis. Ann Dermatol (2010) 0.78
Interleukin-1 receptors are differentially expressed in normal and psoriatic T cells. Mediators Inflamm (2014) 0.78
Experimentally induced psoriatic lesion associates with interleukin (IL)-6 in mast cells and appearance of dermal cells expressing IL-33 and IL-6 receptor. Clin Exp Immunol (2012) 0.77
Impaired hapten sensitization in patients with autoimmune disease. Clin Exp Immunol (2011) 0.76
Transcriptional network profile on synovial fluid T cells in psoriatic arthritis. Clin Rheumatol (2015) 0.76
Current and potential immune therapies and vaccines in the management of psoriasis. Hum Vaccin Immunother (2014) 0.75
Immunophenotype lymphocyte of peripheral blood in patients with psoriasis. Med Arch (2014) 0.75
In vitro induced CD8+ regulatory T cells inhibit skin inflammation. Eur J Microbiol Immunol (Bp) (2011) 0.75
Attenuation of peripheral regulatory T-cell suppression of skin-homing CD8⁺T cells in atopic dermatitis. Yonsei Med J (2015) 0.75
T-cell inhibitors: a bench-to-bedside review. Dermatitis (2012) 0.75
Human IDO-competent, long-lived immunoregulatory dendritic cells induced by intracellular pathogen, and their fate in humanized mice. Sci Rep (2017) 0.75
Autoreactive T Cells from Patients with Myasthenia Gravis Are Characterized by Elevated IL-17, IFN-γ, and GM-CSF and Diminished IL-10 Production. J Immunol (2016) 0.75
Rational Vehicle Design Ensures Targeted Cutaneous Steroid Delivery. J Clin Aesthet Dermatol (2017) 0.75
Effect of 12-O-tetradecanoylphorbol-13-acetate-induced psoriasis-like skin lesions on systemic inflammation and atherosclerosis in hypercholesterolaemic apolipoprotein E deficient mice. BMC Dermatol (2016) 0.75
Frequently Increased but Functionally Impaired CD4+CD25+ Regulatory T Cells in Patients with Oral Lichen Planus. Inflammation (2016) 0.75
Withasteroid B from D. metel L. regulates immune responses by modulating the JAK/STAT pathway and the IL-17(+) RORγt(+) /IL-10(+) FoxP3(+) ratio. Clin Exp Immunol (2017) 0.75
Control of regulatory T cell development by the transcription factor Foxp3. Science (2003) 40.32
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol (2003) 38.57
Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol (1995) 29.42
An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol (2003) 19.16
CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med (1998) 19.03
Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med (2000) 16.09
B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity (2000) 15.44
Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med (2000) 13.13
Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol (1998) 11.26
CD4+CD25high regulatory cells in human peripheral blood. J Immunol (2001) 11.25
Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. J Immunol (2000) 9.15
Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med (2004) 8.98
Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol (1999) 8.98
Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J Exp Med (1996) 8.54
Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J Exp Med (2001) 7.86
Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J Exp Med (2001) 7.46
CD4+CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J Immunol (1998) 7.31
Regulatory T cells in the control of immune pathology. Nat Immunol (2001) 6.98
Human cd25(+)cd4(+) t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med (2001) 6.22
Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med (2001) 5.67
Antigen-dependent proliferation of CD4+ CD25+ regulatory T cells in vivo. J Exp Med (2003) 5.23
Human CD4(+)CD25(+) thymocytes and peripheral T cells have immune suppressive activity in vitro. Eur J Immunol (2001) 4.58
Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells. J Exp Med (2003) 4.41
Clustering of non-major histocompatibility complex susceptibility candidate loci in human autoimmune diseases. Proc Natl Acad Sci U S A (1998) 3.35
Defective suppressor function of human CD4+ CD25+ regulatory T cells in autoimmune polyglandular syndrome type II. J Exp Med (2004) 2.73
Dermal injection of immunocytes induces psoriasis. J Clin Invest (1996) 2.64
Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells. Nature (1997) 2.56
Evidence for two psoriasis susceptibility loci (HLA and 17q) and two novel candidate regions (16q and 20p) by genome-wide scan. Hum Mol Genet (1997) 2.48
Effects of cyclosporine on cytokines and cytokine receptors in psoriasis. J Am Acad Dermatol (1995) 2.14
Abnormal cell proliferation in psoriasis. J Invest Dermatol (1968) 1.85
Characterization of dermal dendritic cells in psoriasis. Autostimulation of T lymphocytes and induction of Th1 type cytokines. J Clin Invest (1994) 1.71
Persistence of T-cell clones in psoriatic lesions. Arch Dermatol (1997) 1.52
Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate. Eur J Immunol (1996) 1.52
Identification and quantitation of interferon-gamma producing T cells in psoriatic lesions: localization to both CD4+ and CD8+ subsets. J Invest Dermatol (1998) 1.36
Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+) cells. J Immunol (2002) 1.23
T cell clones from psoriasis skin lesions can promote keratinocyte proliferation in vitro via secreted products. Eur J Immunol (1994) 1.23
CD69, HLA-DR and the IL-2R identify persistently activated T cells in psoriasis vulgaris lesional skin: blood and skin comparisons by flow cytometry. J Autoimmun (2000) 1.13
Selective targeting of T cell subsets: focus on alefacept - a remittive therapy for psoriasis. Expert Opin Biol Ther (2002) 1.09
Proliferating cells in psoriatic dermis are comprised primarily of T cells, endothelial cells, and factor XIIIa+ perivascular dendritic cells. J Invest Dermatol (1991) 1.09
Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. J Am Acad Dermatol (2000) 1.07
Immunological responses of patients with psoriasis and the effect of treatment with methotrexate. Br J Dermatol (1975) 1.06
In vivo ultraviolet-exposed human epidermal cells activate T suppressor cell pathways that involve CD4+CD45RA+ suppressor-inducer T cells. J Immunol (1990) 0.92
The mechanisms of action of cyclosporin A in the treatment of psoriasis. Immunol Today (1993) 0.91
Treatment of severe psoriasis with anti-CD25 monoclonal antibodies. Arch Dermatol (2000) 0.90
Fibronectin and alpha5 integrin regulate keratinocyte cell cycling. A mechanism for increased fibronectin potentiation of T cell lymphokine-driven keratinocyte hyperproliferation in psoriasis. J Clin Invest (1998) 0.90
The role of the immune system in the pathogenesis of psoriasis. J Invest Dermatol (1990) 0.85
Early migration of cutaneous lymphocyte-associated antigen (CLA) positive T cells into evolving psoriatic plaques. Exp Dermatol (2001) 0.85
Skin-infiltrating lymphocytes in normal and disordered skin: activation signals and functional roles in psoriasis and mycosis fungoides-type cutaneous T cell lymphoma. J Dermatol (1992) 0.84
T lymphocytes derived from skin lesions of patients with psoriasis vulgaris express a novel cytokine pattern that is distinct from that of T helper type 1 and T helper type 2 cells. Eur J Immunol (1994) 0.84
The development and use of T cell receptor peptide vaccines. Adv Exp Med Biol (1995) 0.79
Use of indoor tanning facilities by white adolescents in the United States. Arch Pediatr Adolesc Med (2003) 3.16
A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol (2004) 2.96
Fusobacterium nucleatum induces premature and term stillbirths in pregnant mice: implication of oral bacteria in preterm birth. Infect Immun (2004) 2.47
Hair follicle stem cell-specific PPARgamma deletion causes scarring alopecia. J Invest Dermatol (2008) 2.23
The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol (2002) 2.10
Prognosis of patients with transected melanomas. Dermatol Surg (2013) 2.04
Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association "Administrative Regulations for Evidence-Based Clinical Practice Guidelines". J Am Acad Dermatol (2004) 1.81
IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells. J Immunol (2009) 1.77
Sunlight, tanning booths, and vitamin D. J Am Acad Dermatol (2005) 1.68
Consensus conference on pediatric atopic dermatitis. J Am Acad Dermatol (2003) 1.68
Photodynamic therapy with the phthalocyanine photosensitizer Pc 4: the case experience with preclinical mechanistic and early clinical-translational studies. Toxicol Appl Pharmacol (2007) 1.64
Osteopontin is produced by mast cells and affects IgE-mediated degranulation and migration of mast cells. Eur J Immunol (2008) 1.62
TLR3-, TLR7-, and TLR9-mediated production of proinflammatory cytokines and chemokines from murine connective tissue type skin-derived mast cells but not from bone marrow-derived mast cells. J Immunol (2004) 1.61
Severe dermatomyositis triggered by interferon beta-1a therapy and associated with enhanced type I interferon signaling. Arch Dermatol (2008) 1.58
Antimicrobial peptide LL-37 produced by HSV-2-infected keratinocytes enhances HIV infection of Langerhans cells. Cell Host Microbe (2013) 1.56
Cost-effectiveness analysis of tacrolimus ointment versus high-potency topical corticosteroids in adults with moderate to severe atopic dermatitis. J Am Acad Dermatol (2003) 1.55
An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. J Immunol (2006) 1.54
High ultraviolet A protection affords greater immune protection confirming that ultraviolet A contributes to photoimmunosuppression in humans. J Invest Dermatol (2003) 1.47
Differences in binding and effector functions between classes of TNF antagonists. Cytokine (2009) 1.46
Oral administration of the CCR5 inhibitor, maraviroc, blocks HIV ex vivo infection of Langerhans cells within the epithelium. J Invest Dermatol (2013) 1.44
Usefulness of flow cytometry in the diagnosis of mycosis fungoides. J Am Acad Dermatol (2007) 1.41
Keratinocyte but not endothelial cell-specific overexpression of Tie2 leads to the development of psoriasis. Am J Pathol (2009) 1.32
Stat3 phosphorylation mediates resistance of primary human T cells to regulatory T cell suppression. J Immunol (2011) 1.26
Cost of atopic dermatitis and eczema in the United States. J Am Acad Dermatol (2002) 1.26
A Case of Metastatic Extramammary Paget's Disease Responding to Trastuzumab plus Paclitaxel Combination Therapy. Case Rep Dermatol (2011) 1.20
Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation. J Immunol (2013) 1.20
A case of lymphoepithelioma-like carcinoma of the skin associated with Epstein-Barr virus infection. J Am Acad Dermatol (2010) 1.17
Interaction of Candida albicans with adherent human peripheral blood mononuclear cells increases C. albicans biofilm formation and results in differential expression of pro- and anti-inflammatory cytokines. Infect Immun (2007) 1.16
A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis. Curr Med Res Opin (2007) 1.11
Case of subcutaneous sparganosis: use of imaging in definitive preoperative diagnosis. J Dermatol (2007) 1.09
Ultraviolet immunosuppression: mechanisms and consequences. Dermatol Clin (2006) 1.09
Quantifying skin disease burden in mycosis fungoides-type cutaneous T-cell lymphomas: the severity-weighted assessment tool (SWAT). Arch Dermatol (2002) 1.08
Computerized interactive educational tools used to improve use of sun-protective clothing and sunscreen: a randomized controlled study. Arch Dermatol (2012) 1.08
Silicon phthalocyanine (Pc 4) photodynamic therapy is a safe modality for cutaneous neoplasms: results of a phase 1 clinical trial. Lasers Surg Med (2010) 1.07
Improvement in Patient Performance of Skin Self-examinations After Intervention With Interactive Education and Telecommunication Reminders: A Randomized Controlled Study. Arch Dermatol (2012) 1.05
Sphingosine 1-phosphate accelerates wound healing in diabetic mice. J Dermatol Sci (2007) 1.04
The effects of endothelin-1 on degranulation, cytokine, and growth factor production by skin-derived mast cells. Eur J Immunol (2004) 1.03
Apoptosis mechanisms related to the increased sensitivity of Jurkat T-cells vs A431 epidermoid cells to photodynamic therapy with the phthalocyanine Pc 4. Photochem Photobiol (2008) 1.02
Quantification of human beta-defensin-2 and -3 in body fluids: application for studies of innate immunity. Clin Chem (2007) 1.01
Inhibition of monocytic interleukin-12 production by Candida albicans via selective activation of ERK mitogen-activated protein kinase. Infect Immun (2004) 1.01
Gram-positive bacteria enhance HIV-1 susceptibility in Langerhans cells, but not in dendritic cells, via Toll-like receptor activation. Blood (2009) 1.01
The role of Langerhans cells in the sexual transmission of HIV. J Dermatol Sci (2005) 1.00
Intratumoral injection of immature dendritic cells enhances antitumor effect of hyperthermia using magnetic nanoparticles. Int J Cancer (2005) 1.00
Generation of a large number of connective tissue type mast cells by culture of murine fetal skin cells. J Invest Dermatol (2003) 1.00
Morphine, oxycodone, and fentanyl exhibit different analgesic profiles in mouse pain models. J Pharmacol Sci (2009) 0.99
Chronic skin-specific inflammation promotes vascular inflammation and thrombosis. J Invest Dermatol (2012) 0.99
Modification of surface properties of biomaterials influences the ability of Candida albicans to form biofilms. Appl Environ Microbiol (2005) 0.99
Physical and mental impact of psoriasis severity as measured by the compact Short Form-12 Health Survey (SF-12) quality of life tool. J Invest Dermatol (2011) 0.98
Mechanisms underlying the dysfunction of melanocytes in vitiligo epidermis: role of SCF/KIT protein interactions and the downstream effector, MITF-M. J Pathol (2004) 0.98
Regulation generation: the suppressive functions of human regulatory T cells. Crit Rev Immunol (2012) 0.98
Factors that affect skin aging: a cohort-based survey on twins. Arch Dermatol (2009) 0.98
Mast cells play a key role in host defense against herpes simplex virus infection through TNF-α and IL-6 production. J Invest Dermatol (2013) 0.98
Topical application of green and white tea extracts provides protection from solar-simulated ultraviolet light in human skin. Exp Dermatol (2009) 0.97
The sensitivity of Medicare data for identifying incident cases of invasive melanoma (United States). Cancer Causes Control (2004) 0.97
IL-17 in psoriasis: implications for therapy and cardiovascular co-morbidities. Cytokine (2013) 0.95
Significant virus replication in Langerhans cells following application of HIV to abraded skin: relevance to occupational transmission of HIV. J Immunol (2008) 0.95
Signal peptide cleavage is essential for surface expression of a regulatory T cell surface protein, leucine rich repeat containing 32 (LRRC32). BMC Biochem (2011) 0.95
Overexpression of GRIM-19 in cancer cells suppresses STAT3-mediated signal transduction and cancer growth. Mol Cancer Ther (2010) 0.94
Clinical characteristics of psoriatic arthritis and psoriasis in dermatologists' offices. J Dermatolog Treat (2006) 0.94
Gap junction-mediated intercellular communication between dendritic cells (DCs) is required for effective activation of DCs. J Immunol (2006) 0.94
Most Highly Cytokinergic IgEs Have Polyreactivity to Autoantigens. Allergy Asthma Immunol Res (2012) 0.93
Binding characteristics of tumor necrosis factor receptor-Fc fusion proteins vs anti-tumor necrosis factor mAbs. J Investig Dermatol Symp Proc (2007) 0.92
Epithelial cell-derived antimicrobial peptides are multifunctional agents that bridge innate and adaptive immunity. Periodontol 2000 (2010) 0.92
Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2. Melanoma Res (2003) 0.92
Photodynamic therapy with Pc 4 induces apoptosis of Candida albicans. Photochem Photobiol (2011) 0.92
Rat-bite fever identified by polymerase chain reaction detection of Streptobacillus moniliformis DNA. J Dermatol (2008) 0.91
A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol (2006) 0.91
Approaches to repigmentation of vitiligo skin: new treatment with ultrasonic abrasion, seed-grafting and psoralen plus ultraviolet A therapy. Pigment Cell Res (2002) 0.91
Circumscribed palmo-plantar hypokeratosis: a disease with two subtypes. J Invest Dermatol (2008) 0.91
Improving chemotherapeutic drug penetration in melanoma by imatinib mesylate. J Dermatol Sci (2008) 0.90
Cutaneous hypersensitivity to Candida albicans in idiopathic vulvodynia. Contact Dermatitis (2005) 0.90
Cutaneous lymphoid hyperplasia: a lymphoproliferative continuum with lymphomatous potential. Hum Pathol (2003) 0.90
Psoriasis patients exhibit impairment of the high potency CCR5(+) T regulatory cell subset. Clin Immunol (2013) 0.89
Carbonic anhydrase II is a tumor vessel endothelium-associated antigen targeted by dendritic cell therapy. Clin Cancer Res (2005) 0.89
Electrochemotherapy of cutaneous metastases of melanoma--a case series study and systematic review of the evidence. Dermatol Surg (2011) 0.88
Pathophysiology of atopic dermatitis. Clin Dermatol (2003) 0.88
Fusobacterium nucleatum-associated beta-defensin inducer (FAD-I): identification, isolation, and functional evaluation. J Biol Chem (2010) 0.88
The yin and yang of human Beta-defensins in health and disease. Front Immunol (2012) 0.88
A patient with pseudochromhidrosis presenting with pink nails. J Am Acad Dermatol (2012) 0.88